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background: Spironolactone is known to improve survival in patients with left ventricular failure. However, it is unclear whether it provides a 
survival benefit in patients with isolated right ventricular failure secondary to pulmonary hypertension (PH). We aimed to examine the effect of 
spironolactone on survival in this patient population.
methods: From January 2002 to August 2012, transthoracic echocardiograms from 3 hospitals of Montefiore Medical Center were reviewed and 
all consecutive patients with age ≥18 years, severe PH defined by a pulmonary artery systolic pressure ≥65 mmHg, right ventricular hypokinesis, 
and left ventricular ejection fraction ≥50% were enrolled in this study. Patients were divided into two groups based on whether or not they were on 
spironolactone therapy for 12 consecutive months after diagnosis of PH. Primary endpoint was 1-year all-cause mortality and secondary endpoint 
was 1-year hospital readmission. Inpatient and social security death records were used to determine mortality; hospital records were used to 
determine hospital readmission for acute PH or corpulmonale.
results: Of 2,194 patients included (age 71±16; 31% male), 91 (4%) patients were on spironolactone therapy. In the entire population, 1-year 
mortality was 32.3% and readmission was 3.3%. Mortality and readmission rates were not statistically different between spironolactone and no-
spironolactone groups (25.3% vs 32.6%, RR 0.70 [95% CI 0.47, 1.07], p=NS, and 6.6% vs 3.4%, RR 1.88 [95% CI 0.82, 4.34], p=NS, respectively).
conclusions: In a multicenter study, we investigated for the first time the clinical effect of spironolactone therapy in patients with isolated right 
ventricular failure secondary to severe PH, and observed no survival benefit for spironolactone therapy. While right ventricular failure is the primary 
cause of death in patients with PH, our results warrant importance of information regarding mechanisms of renal sodium and water retention in this 
setting.
